Targets › TROP-2
1 program from 1 company in 44 trials: 24 Phase 2, 15 Phase 3, 5 Phase 1; Gastroenterology, Oncology; next expected readout Nov 2026.
Open in Phaseline: the race on TROP-2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sichuan Baili Pharmaceutical | BL-B01D1 Anti-TROP2 antibody-drug conjugate | TROP-2, TROP2, TACSTD2 | Phase 3 | Nasopharyngeal Carcinoma; Small Cell Lung Cancer; Non-small Cell Lung Cancer; Epithelial Ovarian Cancer … | Nov 2026 |
Non-small Cell Lung Cancer (8) Urothelial Carcinoma (3) Breast Cancer (3) Small Cell Lung Cancer (2) Esophageal Squamous Cell Carcinoma (2) Extensive-stage Small-cell Lung Cancer (2) Cervical Cancer (2) Head and Neck Squamous Cell Carcinoma (2) Nasopharyngeal Carcinoma (1) Epithelial Ovarian Cancer (1) Triple-Negative Breast Cancer (1) HR+HER2- Breast Cancer (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.